2:15 PM
 | 
Mar 21, 2017
 |  BC Extra  |  Clinical News

Scripps researchers design new ADCs

Researchers from The Scripps Research Institute have designed antibodies based on engineered selenocysteine residues that they say can be used to produce highly stable, potent, and selective antibody-drug conjugates. In a paper published in Cell Chemical Biology, the researchers showed ADCs made with the engineered antibodies were effective in mouse models of breast cancer and multiple myeloma.

The paper's authors sought to avoid an extra step required when conjugating...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >